GleamWall
中文EN

INSM INSMED Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1104506 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY240.0%
TTM net income YoY48.8%
TTM EPS YoY54.6%
Revenue 3-yr CAGR75.6%
Net income 3-yr CAGR—

Margins

Gross margin84.4%
Operating margin-37.1%
Net margin-39.9%
FCF margin-41.3%
EBITDA margin-36.3%

Returns

ROE-72.5%
ROA-26.4%
ROIC (approx.)-43.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets67.4%
Debt / equity0.76x
Current ratio2.86x
Interest coverage-6.93x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$606.42M$363.71M
Cost of revenue$122.94M$85.74M
Gross profit$483.49M$277.96M
R&D expense$771.09M$598.37M
SG&A expense$701.17M$461.12M
Operating income-$1.25B-$878.25M
Interest expense$83.80M$84.91M
Pretax income-$1.27B-$910.07M
Income tax$5.03M$3.71M
Net income-$1.28B-$913.77M
EBITDA-$1.24B-$872.29M
EPS (basic)-6.42-5.57
EPS (diluted)-6.42-5.57
Weighted avg. shares (diluted)199.01M164.04M
Balance sheet
Cash & equivalents$510.44M$555.03M
Short-term investments$919.60M$878.80M
Receivables$140.86M$52.01M
Inventory$132.07M$98.58M
Current assets$1.79B$1.62B
PP&E, net$102.94M$80.05M
Goodwill$136.11M$136.11M
Intangibles$97.65M$58.65M
Total assets$2.26B$2.03B
Current liabilities$468.87M$297.53M
Short-term debt$0—
Long-term debt$540.96M$1.10B
Total debt$540.96M$1.10B
Total liabilities$1.53B$1.74B
Shareholders' equity$738.98M$285.38M
Net debt$30.52M$548.35M
Shares outstanding214.26M179.38M
Cash flow statement
Operating cash flow-$935.01M-$683.88M
Capital expenditure$32.56M$21.92M
Free cash flow-$967.58M-$705.80M
Investing cash flow-$64.58M-$583.17M
Financing cash flow$954.07M$1.34B
Depreciation & amortization$10.45M$5.96M
Stock-based compensation$152.71M$96.83M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.